Sebacia Announces New Vice President, Engineering And Program Management

DULUTH, Ga., June 25, 2015 /PRNewswire/ -- Sebacia, Inc., a company dedicated to delivering breakthrough treatments to advance dermatology, today announced that the company has hired Pedro Medrano as Vice President, Engineering and Program Management. In his new role, Mr. Medrano will lead commercialization readiness for Sebacia Treatment, a potential new in-office procedure for acne, one of the most common dermatological conditions.

The Sebacia Treatment utilizes hair removal lasers, already in routine use among dermatologists, in combination with proprietary Sebacia Gold Microparticles, and is designed to deliver lasting results from a few, simple treatments performed at a dermatologist's office.

"Sebacia is entering an exciting time as we are concluding our U.S. pivotal trial and planning for U.S. and European commercial launches of Sebacia Treatment for moderate to severe acne," said Anthony Lando, Sebacia's CEO. "Pedro's deep experience in product development, particularly in the regulated medical device space, will be extremely valuable in bringing a new, innovative acne treatment to the dermatology market."

In March 2015, two clinical studies demonstrating the efficacy of the Sebacia Treatment for acne were published in the Journal of Investigative Dermatology, considered to be the leading journal in the dermatology field and part of the Nature Publishing Group. Enrollment in a pivotal U.S. clinical trial is currently in process.

"The acne space has not seen major innovation in treatments in decades, and Sebacia is poised to bring to market the first in-office system that is designed to provide sustained relief from acne," said Pedro Medrano. "With clinical data demonstrating efficacy of the Sebacia Treatment and a U.S. pivotal clinical trial underway, Sebacia is well-positioned to launch a commercial product to help many who have struggled with acne."

Prior to joining Sebacia, Mr. Medrano was Director of the Project Management Office for Philips' Nuclear Medicine and Imaging business, responsible for new product development and sustaining programs. During his 15 years at St. Jude Medical, Inc., Mr. Medrano led numerous global, cross-functional teams in the development of Class III implantable devices and systems. He has also held business development positions with Novartis' eye care division (CIBA VISION and Alcon) and The Innovation Factory, where he performed due diligence on refractive laser surgery, intraocular and contact lenses, and drug delivery devices. He earned his B.S. degree in materials science and engineering from Stanford University and an MBA from the UCLA Anderson School of Management.

About Sebacia Microparticles

Made of gold and silica, Sebacia microparticles are specially designed to be activated by the light from commonly used hair removal lasers and are placed in a suspension designed to penetrate the sebaceous follicles. When exposed to a laser pulse, they create a focused photothermal effect in the sebaceous gland and follicle to reduce the activity level of the gland and the inflammatory lesions that cause acne.

About Sebacia

Sebacia Inc. is a clinical-stage, private medical device company dedicated to creating breakthrough topical therapies for the treatment of dermatological conditions affecting millions of people. Sebacia's goal is to provide a better alternative to the daily use of topical and systemic drugs currently available for the treatment of acne. Sebacia's patented microparticles technology was invented at Rice University, and the proprietary dermatology applications were further developed with researchers from the Wellman Center of Photomedicine at Massachusetts General Hospital. Sebacia is located in Duluth, Georgia.

More information is available at www.sebacia.com or follow us at www.twitter.com/SebaciaNews.

Suggested Articles

I-MAB's anti-GM-CSF drug works "upstream" in inflammation pathways, potentially blocking several dangerous cytokines in COVID-19, executives…

Antibe's lead drug beat placebo at reducing osteoarthritis pain, boosting its case as an alternative to NSAIDs, commonly used to treat the condition.

The trial marks the start of a new phase of the response to SARS-CoV-2 in which people will receive drugs designed specifically for the virus.